Over the past decade, “incremental innovation” (pharmaceutical innovations that improve on existing drug therapies) has accounted for 70% of the new drugs approved in the US and a substantial portion of the industry’s revenues. However, concerns that reformulated drugs are being used to delay or preclude generic competition have given rise to a number of high-profile antitrust suits, including cases concerning the drugs BuSpar, Nexium/Prilosec, and DDAVP, among others. Click here to download a PDF of this article:
CRA Competition's response to EU Draft Merger Guidelines: An economic perspective on the emerging framework
Our European Competition team has contributed to the economic assessment in nearly a third of distinct merger decisions cited in the draft, (46 out of 164)...